Drugs Made In America Acquisition II Corp.
DMII
$10.01
$0.000.00%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 1.05M | 155.50K | 38.10K | 59.30K | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 1.05M | 155.50K | 38.10K | 59.30K | |
| Operating Income | -1.05M | -155.50K | -38.10K | -59.30K | |
| Income Before Tax | 4.33M | -46.20K | -38.10K | -59.30K | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | 4.33M | -46.20K | -38.10K | -59.30K | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | 4.33M | -46.20K | -38.10K | -59.30K | |
| EBIT | -1.05M | -155.50K | -38.10K | -59.30K | |
| EBITDA | -- | -- | -- | -- | |
| EPS Basic | 0.07 | 0.00 | 0.00 | 0.00 | |
| Normalized Basic EPS | 0.04 | 0.00 | 0.00 | 0.00 | |
| EPS Diluted | 0.07 | 0.00 | 0.00 | 0.00 | |
| Normalized Diluted EPS | 0.04 | 0.00 | 0.00 | 0.00 | |
| Average Basic Shares Outstanding | 63.70M | 65.58M | 14.38M | 14.38M | |
| Average Diluted Shares Outstanding | 63.70M | 65.58M | 14.38M | 14.38M | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |